Home › Compare › SPMMF vs ABBV
SPMMF yields 224.72% · ABBV yields 3.06%● Live data
📍 SPMMF pulled ahead of the other in Year 1
Combined, SPMMF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SPMMF + ABBV for your $10,000?
Space-Communication Ltd. provides satellite communication services worldwide. The company offers on-the-move connectivity solutions; satellite broadband services, including high-speed two-way internet, broadband internet access, B2B and B2C, point-to-multipoint streaming, congestion-free IP trunking, and on-demand services; and satellite broadcasting services, such as DTH and TV/audio origination and distribution, redundancy and backup, encryption, satellite news gathering, video signals packaging and up-linking, TV channels retransmission, and satellite TV programs broadcasting services. It also provides hybrid cellular-satellite internet solutions; cross-region connectivity services; and satellite teleport services. In addition, the company offers corporate and government network solutions comprising local area network interconnection, VSAT network, satellite VPN, and data transmission services, as well as delivery of video, voice, and data to remote locations, including videoconference, telephony, fax transmissions, etc. Further, it provides point of sale applications, such as ATM and inventory reports; and internet applications. The company was founded in 1989 and is based in Ramat Gan, Israel. Space-Communication Ltd. is a subsidiary of Eurocom Holdings (1979) Ltd.
Full SPMMF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.